Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...
The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results